Abstract 5779
Background
Drug resistance is an important clinical problem affecting the prognosis of colorectal cancer patients with initially unresectable liver metastases. The role of 5-hydroxymethylcytosine (5-hmC) in this process is still unknown.
Methods
A single-center study was conducted to enroll colorectal cancer patients with initially unresectable liver metastases at Zhongshan Hospital, Shanghai. The 5-hmC levels of each gene locus in circulating-free DNA (cfDNA) were detected using a highly sensitive sequencing method before the patient received any conversion therapy. Eight weeks after conversion therapy, patients with disease progression according to RECIST 1.1 were defined as drug-resistant group, while patients with complete response, partial response and stable disease were defined as the drug-effective group. By using the gene loci with the most significant difference of 5-hmC level, a predictive model (Logistic regression) was established based on machine-learning method. Then, we validated the model.
Results
From June 2018 to January 2019, 35 patients were enrolled, including 20 patients in drug-effective group and 15 in drug-resistant group. The predictive model was established using the first 100 significantly different gene loci and 10 loci were included in the model. The internal validation results suggested that the sensitivity (predictive accuracy for drug-resistant patients) and specificity (predictive accuracy for drug-effective patients) were 86.7% and 95.0%, respectively, and the area under the ROC curve is 0.990.
Conclusions
Our study screened the gene loci with different 5-hmC level between drug-effective and drug-resistant colorectal cancer patients with initial unresectable liver metastases. Then we established a predictive model for the efficacy of conversion therapy, although this model is still being improved and validated by enrolling more subjects.
Clinical trial identification
NCT03679039 09/18/2018.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3907 - Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Presenter: Axel Grothey
Session: Poster Display session 2
Resources:
Abstract
3958 - Quality of Life (QoL) in Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results of a European Survey
Presenter: Zorana Maravic
Session: Poster Display session 2
Resources:
Abstract
3563 - BISQUIT: A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal
Presenter: Rachel Riechelmann
Session: Poster Display session 2
Resources:
Abstract
1184 - iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Presenter: Fiona Turkes
Session: Poster Display session 2
Resources:
Abstract
3346 - Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study
Presenter: Lisa Salvatore
Session: Poster Display session 2
Resources:
Abstract
3895 - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study.
Presenter: Maria Aurelia Barbera
Session: Poster Display session 2
Resources:
Abstract
2012 - Open Label Phase III Study of Arfolitixorin vs. Leucovorin in mFOLFOX-6 for First Line Treatment of Metastatic Colorectal Cancer: AGENT
Presenter: Josep Tabernero
Session: Poster Display session 2
Resources:
Abstract
2198 - SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Presenter: Thierry Andre
Session: Poster Display session 2
Resources:
Abstract
2921 - A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (short title CAROSELL)
Presenter: Mark Saunders
Session: Poster Display session 2
Resources:
Abstract
3695 - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
Presenter: Heinz Josef Lenz
Session: Poster Display session 2
Resources:
Abstract